3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia
3
Recurrence
2
Lymphoproliferative Disorders
2
Burkitt Lymphoma
2
Neoplasms
1
Neoplasm, Residual
1
Lymphatic Diseases
1
Immunoproliferative Disorders
1
Interventions
blinatumomab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Neoplasm, Residual
×
blinatumomab
×
Clear all
NCT01207388
2020-02-10
BLAST
Amgen Research (Munich) GmbH
Phase 2
Completed
116 enrolled
23 charts
1 FDA